Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Daily News

MI Risk in Subclinical CAD? Both Extent and Stenosis Severity Matter

Yael L. Maxwell

March 27, 2023

News Conference News AHA 2020

Rilonacept Prevents Recurrent Pericarditis: RHAPSODY

Shelley Wood

November 17, 2020

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

News Daily News

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Yael L. Maxwell

May 15, 2019

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Caitlin E. Cox

November 13, 2018

Presentation ACC 2018

CANTOS: Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

Presenter: Brendan M. Everett

March 12, 2018

News Conference News ACC 2018

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

Michael O'Riordan

March 12, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Shelley Wood

March 12, 2018

News Daily News

Subclinical Atherosclerosis Evident in Half of Adults Without CVD Risk Factors

Michael O'Riordan

December 12, 2017

News Daily News

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

Yael L. Maxwell

January 31, 2017

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

依泽替米贝减少心血管事件的说法未能获得 FDA 顾问委员会的支持

Michael O'Riordan

December 15, 2015

News Daily News

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Michael O'Riordan

December 15, 2015

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

News Daily News

肌钙蛋白 T 水平高预示着 2 型糖尿病及稳定型心脏疾病患者结局不佳

Todd Neale

August 17, 2015

News Daily News

Los Niveles Altos de Troponina T Pronostican Malos Resultados en Pacientes Con Diabetes Tipo 2 y Cardiopatía Estable

Todd Neale

August 17, 2015

News Daily News

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

Todd Neale

August 17, 2015

Advertisement

MI Risk in Subclinical CAD? Both Extent and Stenosis Severity Matter

Rilonacept Prevents Recurrent Pericarditis: RHAPSODY

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

CANTOS: Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Subclinical Atherosclerosis Evident in Half of Adults Without CVD Risk Factors

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

依泽替米贝减少心血管事件的说法未能获得 FDA 顾问委员会的支持

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

肌钙蛋白 T 水平高预示着 2 型糖尿病及稳定型心脏疾病患者结局不佳

Los Niveles Altos de Troponina T Pronostican Malos Resultados en Pacientes Con Diabetes Tipo 2 y Cardiopatía Estable

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content